title: [Measurement of 75Se-SeHCAT abdominal retention in the initial diagnosis of Bile Acid Absorption (BAM)].
abstract: OBJECTIVE
  To evaluate the usefulness of the (75)SeHCAT abdominal retention (AR) measurement in the early diagnosis of diarrhea syndrome (DS).
  
  
  METHODS
  Thirty-seven patients with diarrhea syndrome within the first month of evolution were prospectively evaluated. The (75)Se-SeHCAT abdominal retention was measured 4 and 7 days post-administration of 0.01 mCi of (75)SeHCAT. The test was performed prior to treatment and at 3 months when the baseline study was positive. The test was considered positive if the RA was <25% at 4(th) and <10% on the 7th day. The patients were visited at 3 months. Depending on the response, 3 groups were established: a) complete response: normalization of stool frequency, b) partial response, decrease of frequency or c) no response.
  
  
  RESULTS
  Group A: The AR of (75)Se-SEHCAT was normal in 21 patients. Six were diagnosed of colonic diverticulosis, 8 of irritable bowel syndrome, 1 of lymphocytic colitis, 1 of post-gastroenteritis syndrome, 1 of celiac disease and 1 of stenosis of the cardia. Four are still under study. Group B: The AR of (75)Se-SEHCAT decreased in 16 patients. All showed abnormal AR at day 7 and all but 1 at day 4. Following administration of cholestyramine resin, 8 (50%) presented partial response and 8 (50%) complete response. At 3 months, AR had increased at day 4 and 9 at day 7.
  
  
  CONCLUSIONS
  The measurement of (75)SEHCAT abdominal retention allows the early diagnosis of bile acid malabsorption in 43% of the patients with DS. Measurement at 7 days seems more accurate than that at 4 days.
authors.affiliation: Servicio de Medicina Nuclear y Servicio de Gastroenterología, Hospital Universitari de Bellvitge, Idibell, Hospitalet de Llobregat, Barcelona, España.
authors.forename: P C
authors.initials: PC
authors.lastname: Notta
authors.forename: D
authors.initials: D
authors.lastname: Ramal
authors.forename: S
authors.initials: S
authors.lastname: Maisterra
authors.forename: A
authors.initials: A
authors.lastname: Rodríguez Gasen
authors.forename: S
authors.initials: S
authors.lastname: Maymó
authors.forename: A
authors.initials: A
authors.lastname: Sabaté
authors.forename: A
authors.initials: A
authors.lastname: Girbau
authors.forename: J
authors.initials: J
authors.lastname: Guardiola
authors.forename: J
authors.initials: J
authors.lastname: Martín-Comín
mesh_terms: D000005:Abdomen / Q000000981:diagnostic imaging; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D002299:Cardia / Q000473:pathology; D002446:Celiac Disease / Q000150:complications / Q000175:diagnosis; D002792:Cholestyramine Resin / Q000627:therapeutic use; D002908:Chronic Disease; D046730:Colitis, Lymphocytic / Q000150:complications / Q000175:diagnosis; D003251:Constriction, Pathologic; D003967:Diarrhea / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D043963:Diverticulosis, Colonic / Q000150:complications / Q000175:diagnosis; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D007408:Intestinal Absorption; D043183:Irritable Bowel Syndrome / Q000150:complications / Q000175:diagnosis; D008286:Malabsorption Syndromes / Q000000981:diagnostic imaging* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012644:Selenium Radioisotopes / Q000493:pharmacokinetics; D013656:Taurocholic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D014018:Tissue Distribution
chemical_list: D000924:Anticholesteremic Agents; D019275:Radiopharmaceuticals; D012644:Selenium Radioisotopes; D002792:Cholestyramine Resin; D013656:Taurocholic Acid; C033638:23-seleno-25-homotaurocholic acid